ClinicalTrials.gg
CompletedNCT05660538Updated Jul 1, 2025Results posted

Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)

A Phase 2 interventional study of Suzetrigine and Pregabalin in Diabetic Peripheral Neuropathy, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 50 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-01.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
194
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy and safety of VX-548 doses in treating Painful DPN.

02

Conditions studied

  • Diabetic Peripheral Neuropathy
03

In context

Lead sponsor

Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.

Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosis of diabetes mellitus type 1 or type 2 with

    • Glycosylated (HbA1c) ≤9%; and
    • Presence of bilateral pain in lower extremities due to DPN for at least 1 year

Key Exclusion Criteria:

  • Painful neuropathy other than DPN
  • History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s)
  • History of a clinical atherosclerotic event, such as myocardial infarction or stroke, within the past 12 months

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
194 participants (actual)

Study arms

  • Active comparator
    Pregabalin

    Participants received Pregabalin 100 mg 3 times per day (tid) for 12 weeks

    Drug: Pregabalin · Drug: Placebo (matched to SUZ)

  • Experimental
    Suzetrigine (SUZ): Low Dose

    Participants received SUZ 23 mg tablet once daily (qd) for 12 weeks.

    Drug: Suzetrigine · Drug: Placebo (matched to pregabalin)

  • Experimental
    Suzetrigine (SUZ): Mid Dose

    Participants received SUZ 46 mg tablet qd for 12 weeks.

    Drug: Suzetrigine · Drug: Placebo (matched to pregabalin)

  • Experimental
    Suzetrigine (SUZ): High Dose

    Participants received SUZ 69 mg tablet qd for 12 weeks.

    Drug: Suzetrigine · Drug: Placebo (matched to pregabalin)

Interventions

  • Tablets for oral administration.

    Also known as: VX-548, SUZ

  • Capsules for oral administration.

  • DrugPlacebo (matched to SUZ)

    Placebo matched to SUZ for oral administration.

  • DrugPlacebo (matched to pregabalin)

    Placebo matched to pregabalin for oral administration.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Weekly Average of Daily Pain Intensity on a Numeric Pain Rating Scale (NPRS)

    Change from baseline in the weekly mean of the daily Numeric Pain Rating Scale (NPRS) score assessing average pain intensity in the last 24 hours. Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0= no pain and 10= worst imaginable pain.

    Time frame: Baseline, At Week 12

Secondary outcomes

  1. Change From Baseline in the Weekly Average of the Daily Sleep Interference Scale (DSIS) Score

    Change from baseline in the weekly mean of the Daily Sleep Interference Scale (DSIS) score, which asks participants to describe how pain interfered with the participant's sleep. Response options for the DSIS range from 0 (none) to 10 (severe).

    Time frame: Baseline, At Week 12

  2. Percentage of Participants With Greater Than or Equal to (≥) 30 Percent Reduction From Baseline in the Weekly Average of Daily Pain Intensity on the NPRS

    Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0= no pain and 10= worst imaginable pain. The percentage of participants with ≥30% reduction from baseline in the weekly average NPRS score at Week 12 was reported.

    Time frame: Baseline, At Week 12

  3. Percentage of Participants With ≥50 Percent Reduction From Baseline in the Weekly Average of Daily Pain Intensity on the NPRS

    Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0= no pain and 10= worst imaginable pain.The percentage of participants with ≥50% reduction from baseline in the weekly average NPRS score at Week 12 was reported.

    Time frame: Baseline, At Week 12

  4. Percentage of Participants With ≥70 Percent Reduction From Baseline in the Weekly Average of Daily Pain Intensity on the NPRS

    Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0= no pain and 10= worst imaginable pain. The percentage of participants with ≥70% reduction from baseline in the weekly average NPRS score at Week 12 was reported.

    Time frame: Baseline, At Week 12

  5. Percentage of Participants Categorized as "Much Improved" or "Very Much Improved" on the Patient Global Impression of Change (PGIC) Assessment

    PGIC is an instrument that measures change in participants' overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).

    Time frame: Baseline, At Week 12

  6. Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Day 1 up to Week 14

07

Results

Posted Jul 1, 2025

Participant flow

Participant flow — Overall Study
MilestonePregabalinSuzetrigine (SUZ): Low DoseSuzetrigine (SUZ): Mid DoseSuzetrigine (SUZ): High Dose
Started55285556
Safety set54285555
Modified full analysis set (mfas)49245050
Completed46244647
Not completed9499
Withdrew: Adverse event0010
Withdrew: Withdrawal of consent (not due to ae)1010
Withdrew: Lost to follow-up0011
Withdrew: Death0010
Withdrew: Physician decision0001
Withdrew: Sponsor decision1000
Withdrew: Other1001
Withdrew: Randomized but did not receive study drug1001
Withdrew: Enrolled at clinical trial site excluded from mfas due to lack of compliance with study drug5455

Outcome measures

PrimaryChange From Baseline in the Weekly Average of Daily Pain Intensity on a Numeric Pain Rating Scale (NPRS)

Change from baseline in the weekly mean of the daily Numeric Pain Rating Scale (NPRS) score assessing average pain intensity in the last 24 hours. Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0= no pain and 10= worst imaginable pain.

Time frame:
Baseline, At Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Weekly Average of Daily Pain Intensity on a Numeric Pain Rating Scale (NPRS)
units on a scalePregabalinSuzetrigine (SUZ): Low DoseSuzetrigine (SUZ): Mid DoseSuzetrigine (SUZ): High Dose
Change From Baseline in the Weekly Average of Daily Pain Intensity on a Numeric Pain Rating Scale (NPRS)-2.09 (-2.65 to -1.52)-2.18 (-2.94 to -1.41)-2.11 (-2.67 to -1.55)-2.26 (-2.82 to -1.70)
SecondaryChange From Baseline in the Weekly Average of the Daily Sleep Interference Scale (DSIS) Score

Change from baseline in the weekly mean of the Daily Sleep Interference Scale (DSIS) score, which asks participants to describe how pain interfered with the participant's sleep. Response options for the DSIS range from 0 (none) to 10 (severe).

Time frame:
Baseline, At Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Weekly Average of the Daily Sleep Interference Scale (DSIS) Score
units on a scalePregabalinSuzetrigine (SUZ): Low DoseSuzetrigine (SUZ): Mid DoseSuzetrigine (SUZ): High Dose
Change From Baseline in the Weekly Average of the Daily Sleep Interference Scale (DSIS) Score-2.42 (-3.02 to -1.83)-2.20 (-3.00 to -1.41)-2.44 (-3.01 to -1.87)-2.15 (-2.74 to -1.55)
SecondaryPercentage of Participants With Greater Than or Equal to (≥) 30 Percent Reduction From Baseline in the Weekly Average of Daily Pain Intensity on the NPRS

Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0= no pain and 10= worst imaginable pain. The percentage of participants with ≥30% reduction from baseline in the weekly average NPRS score at Week 12 was reported.

Time frame:
Baseline, At Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Greater Than or Equal to (≥) 30 Percent Reduction From Baseline in the Weekly Average of Daily Pain Intensity on the NPRS
percentage of participantsPregabalinSuzetrigine (SUZ): Low DoseSuzetrigine (SUZ): Mid DoseSuzetrigine (SUZ): High Dose
Percentage of Participants With Greater Than or Equal to (≥) 30 Percent Reduction From Baseline in the Weekly Average of Daily Pain Intensity on the NPRS44.970.846.048.0
SecondaryPercentage of Participants With ≥50 Percent Reduction From Baseline in the Weekly Average of Daily Pain Intensity on the NPRS

Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0= no pain and 10= worst imaginable pain.The percentage of participants with ≥50% reduction from baseline in the weekly average NPRS score at Week 12 was reported.

Time frame:
Baseline, At Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With ≥50 Percent Reduction From Baseline in the Weekly Average of Daily Pain Intensity on the NPRS
percentage of participantsPregabalinSuzetrigine (SUZ): Low DoseSuzetrigine (SUZ): Mid DoseSuzetrigine (SUZ): High Dose
Percentage of Participants With ≥50 Percent Reduction From Baseline in the Weekly Average of Daily Pain Intensity on the NPRS22.441.732.034.0
SecondaryPercentage of Participants With ≥70 Percent Reduction From Baseline in the Weekly Average of Daily Pain Intensity on the NPRS

Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0= no pain and 10= worst imaginable pain. The percentage of participants with ≥70% reduction from baseline in the weekly average NPRS score at Week 12 was reported.

Time frame:
Baseline, At Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With ≥70 Percent Reduction From Baseline in the Weekly Average of Daily Pain Intensity on the NPRS
percentage of participantsPregabalinSuzetrigine (SUZ): Low DoseSuzetrigine (SUZ): Mid DoseSuzetrigine (SUZ): High Dose
Percentage of Participants With ≥70 Percent Reduction From Baseline in the Weekly Average of Daily Pain Intensity on the NPRS10.28.322.022.0
SecondaryPercentage of Participants Categorized as "Much Improved" or "Very Much Improved" on the Patient Global Impression of Change (PGIC) Assessment

PGIC is an instrument that measures change in participants' overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).

Time frame:
Baseline, At Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Categorized as "Much Improved" or "Very Much Improved" on the Patient Global Impression of Change (PGIC) Assessment
percentage of participantsPregabalinSuzetrigine (SUZ): Low DoseSuzetrigine (SUZ): Mid DoseSuzetrigine (SUZ): High Dose
Percentage of Participants Categorized as "Much Improved" or "Very Much Improved" on the Patient Global Impression of Change (PGIC) Assessment46.950.052.050.0
SecondarySafety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame:
Day 1 up to Week 14
Reported as:
Count of participants · Participants
Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsPregabalinSuzetrigine (SUZ): Low DoseSuzetrigine (SUZ): Mid DoseSuzetrigine (SUZ): High Dose
Participants with TEAEs20142131
Participants with SAEs1021

Adverse events

Collected over Day 1 up to Week 14. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pregabalin0/54 (0%)1/54 (1.9%)12/54 (22.2%)
Suzetrigine (SUZ): Low Dose0/28 (0%)0/28 (0%)4/28 (14.3%)
Suzetrigine (SUZ): Mid Dose1/55 (1.8%)2/55 (3.6%)5/55 (9.1%)
Suzetrigine (SUZ): High Dose0/55 (0%)1/55 (1.8%)7/55 (12.7%)
Most frequent serious events
Most frequent serious events
EventPregabalinSuzetrigine (SUZ): Low DoseSuzetrigine (SUZ): Mid DoseSuzetrigine (SUZ): High Dose
Atrial fibrillationCardiac disorders1/540/280/550/55
CellulitisInfections and infestations0/540/280/551/55
HypoglycaemiaMetabolism and nutrition disorders0/540/281/550/55
ArteriosclerosisVascular disorders0/540/281/550/55
Most frequent other events
Most frequent other events
EventPregabalinSuzetrigine (SUZ): Low DoseSuzetrigine (SUZ): Mid DoseSuzetrigine (SUZ): High Dose
Creatinine renal clearance decreasedInvestigations1/540/281/556/55
Back painMusculoskeletal and connective tissue disorders0/543/280/550/55
DizzinessNervous system disorders5/540/281/550/55
Weight increasedInvestigations4/540/280/550/55
Oedema peripheralGeneral disorders3/541/280/550/55
HeadacheNervous system disorders2/540/283/551/55

Baseline characteristics

Baseline data was analyzed based on the Modified Full Analysis Set (mFAS), defined as all randomized participants who have received at least 1 dose of study drug and are not from Site 115.

Age, Continuous
Age, Continuous(years)PregabalinSuzetrigine (SUZ): Low DoseSuzetrigine (SUZ): Mid DoseSuzetrigine (SUZ): High DoseTotal
Mean63.0 ± 7.960.9 ± 6.661.7 ± 8.661.4 ± 8.861.9 ± 8.2
Sex: Female, Male
Sex: Female, Male(Participants)PregabalinSuzetrigine (SUZ): Low DoseSuzetrigine (SUZ): Mid DoseSuzetrigine (SUZ): High DoseTotal
Female2212222177
Male2712282996
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PregabalinSuzetrigine (SUZ): Low DoseSuzetrigine (SUZ): Mid DoseSuzetrigine (SUZ): High DoseTotal
Hispanic or Latino729422
Not Hispanic or Latino42224146151
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PregabalinSuzetrigine (SUZ): Low DoseSuzetrigine (SUZ): Mid DoseSuzetrigine (SUZ): High DoseTotal
White32153335115
Black or African American167151452
Asian00202
American Indian or Alaska Native10012
Other01001
Multiracial01001
Baseline Weekly Average Pain Intensity as Recorded on Numeric Pain Rating Scale (NPRS)
Baseline Weekly Average Pain Intensity as Recorded on Numeric Pain Rating Scale (NPRS)(units on a scale)PregabalinSuzetrigine (SUZ): Low DoseSuzetrigine (SUZ): Mid DoseSuzetrigine (SUZ): High DoseTotal
Mean5.99 ± 1.275.70 ± 1.325.88 ± 0.975.83 ± 1.235.87 ± 1.18
08

Study locations

50 sites
  • Pinnacle Research Group, LLC
    Anniston, Alabama 36207, United States
  • Synexus Clinical Research US - Birmingham
    Birmingham, Alabama 35211, United States
  • Synexus Clinical Research US - Phoenix West
    Phoenix, Arizona 85020, United States
  • Velocity Clinical Research - Banning
    Banning, California 92220, United States
  • Long Beach Clinical Trials Services, Inc.
    Long Beach, California 90806, United States
  • University Clinical Investigators
    Tustin, California 92780, United States
  • Lynn Institute of the Rockies
    Colorado Springs, Colorado 80918, United States
  • Fleming Island Center for Clinical Research
    Fleming Island, Florida 32003, United States
  • AMR Fort Myers (The Clinical Study Center)
    Fort Myers, Florida 33912, United States
  • Velocity Clinical Research - Hallandale Beach
    Hallandale, Florida 33009-4427, United States
  • Westside Center for Clinical Research
    Jacksonville, Florida 32205, United States
  • Accel Research Sites - Tampa
    Largo, Florida 33777, United States
  • Accel Research Sites - Maitland
    Maitland, Florida 32751, United States
  • Suncoast Research Associates
    Miami, Florida 33137, United States
  • Synexus - Orlando
    Orlando, Florida 32806-1041, United States
  • Synexus - The Villages
    The Villages, Florida 32162-7116, United States
  • Accel Research Sites - Neurostudies
    Decatur, Georgia 30030, United States
  • Velocity Clinical Research - Boise (Advanced Clinical Research)
    Meridian, Idaho 83642, United States
  • Healthcare Research Network - Chicago
    Flossmoor, Illinois 60422, United States
  • Synexus Clinical Research - Evansville
    Evansville, Indiana 47714, United States
  • AMR El Dorado
    El Dorado, Kansas 67042, United States
  • AMR Newton
    Newton, Kansas 67114, United States
  • AMR Wichita East, KS
    Wichita, Kansas 67207, United States
  • Clinical Trials of America, LLC
    Monroe, Louisiana 71201, United States
  • Brigham and Women's Hospital (BWH) - Translational Pain Research
    Boston, Massachusetts 02115, United States
  • Boston Neuro Research Center, LLC
    North Dartmouth, Massachusetts 02747, United States
  • Boston PainCare Center
    Waltham, Massachusetts 02451, United States
  • Revival Research Institute
    Dearborn, Michigan 48126, United States
  • StudyMetrix Research, LLC
    City of Saint Peters, Missouri 63303-3041, United States
  • Healthcare Research Network - Hazelwood
    Hazelwood, Missouri 63042, United States
  • AMR Kansas City
    Kansas City, Missouri 64114-4866, United States
  • Synexus Clinical Research US - St. Louis
    St Louis, Missouri 63141, United States
  • Synexus Clinical Research - Henderson
    Henderson, Nevada 89052, United States
  • Hassman Research Institute
    Berlin, New Jersey 08009, United States
  • Synexus Clinical Research- New York
    New York, New York 10017, United States
  • Carolina Institute for Clinical Research
    Fayetteville, North Carolina 28303, United States
  • Triad Clinical Trials
    Greensboro, North Carolina 27410, United States
  • The Center for Clinical Research
    Winston-Salem, North Carolina 27103, United States
  • Synexus - Cincinnati
    Cincinnati, Ohio 45236, United States
  • Velocity Clinical Research - Cleveland
    Cleveland, Ohio 44122, United States
  • Velocity Clinical Research - Medford
    Medford, Oregon 97504, United States
  • Velocity Clinical Research - Providence
    East Greenwich, Rhode Island 02818, United States
  • Synexus Clinical Research- Anderson
    Anderson, South Carolina 29621, United States
  • Clinical Trials of South Carolina - Charleston
    Charleston, South Carolina 29406, United States
  • South Carolina Clinical Research
    Orangeburg, South Carolina 29118, United States
  • Inquest Clinical Research
    Baytown, Texas 77521, United States
  • Synexus - Dallas
    Dallas, Texas 75234-7858, United States
  • Diabetes & Glandular Disease Clinic, P.A
    San Antonio, Texas 78229-4801, United States
  • Wasatch Clinical Research
    Salt Lake City, Utah 84107, United States
  • Northwest Clinical Research Center (NWCRC)
    Bellevue, Washington 98007-4209, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2022 to primary completion in Oct 2023, 9 months.

Results were first posted in Jul 2025, 1 year 8 months after primary completion. A results delay was requested in Oct 2024.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2022
First posted
Dec 21, 2022
StartActual
Dec 20, 2022
Primary completionActual
Oct 12, 2023
CompletionActual
Oct 25, 2023
Results delay requested
Oct 10, 2024
Results first posted
Jul 1, 2025
Last update
Jul 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05660538
Responsible party
Sponsor
First posted
Dec 21, 2022
Start date
Dec 20, 2022
Primary completion
Oct 12, 2023
Completion
Oct 25, 2023
Results posted
Jul 1, 2025
Last update
Jul 1, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Suzetrigine

Start the discussion